Rosetta Genomics (ROSG), Precision Therapeutics Enter miRview Co-Marketing Agreement

Rosetta Genomics Ltd. (Nasdaq: ROSG), has entered into a co-marketing agreement for its miRview mets2 assay for the accurate identification of the tumor of origin in Cancers of Unknown or Uncertain Primary ("CUP") with Precision Therapeutics Inc., a life science company known for its expertise in the science of personalizing cancer therapy by advancing genomic testing and bioinformatics.

Under the terms of the agreement, Rosetta Genomics granted Precision Therapeutics the co-exclusive right, along with Rosetta Genomics, to co-market the miRview® mets2 assay in the U.S. through July 30, 2014, with certain pre-specified performance milestones. Rosetta Genomics will continue to record all revenues for miRview® mets2 and will remain responsible for sample collection, processing and billing. Precision Therapeutics, with one of the largest sales forces in oncology diagnostics and considerable experience in the personalized medicine sector, is expected to launch its miRview® mets2 co-marketing effort in August 2012.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Veeva Systems names Dan Rizzo EVP of sales amid leadership change
• iSpecimen ships hundreds of cancer specimens internationally in 3 weeks
• Splash Beverage Group Inc. (SBEV) files for 5M share offering by selling stockholders